Alyson Fox, MD
Transplant Hepatology · New York, NYNPI 1114136967
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 42.6% of the total. 2025 is the largest year on record at $5,575, more than ten times the $387 reported in 2019.
Across 62 payments — averaging $157.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$4K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Madrigal Pharmaceuticals$523
- Gilead$374
- Alnylam Pharmaceuticals Inc.$278
- Paragonix Technologies, Inc.$239
- plus $2K from 16 others
What the payments were for
- Consulting fees$2,59527%
- Speaking & faculty fees$3,84039%
- Travel & lodging$1441%
- Food & beverage$3,17433%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 5 | $4,158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,595 |
| Madrigal Pharmaceuticals | 11 | $523 |
| Gilead | 5 | $374 |
| Alnylam Pharmaceuticals Inc. | 10 | $278 |
| Paragonix Technologies, Inc. | 1 | $239 |
| Trisalus Life Sciences, Inc. | 1 | $229 |
| Fujifilm Healthcare Americas Corporation | 2 | $208 |
| Mallinckrodt Hospital Products Inc. | 3 | $190 |
| Orphalan Inc | 2 | $176 |
| Dova Pharmaceuticals | 2 | $156 |
| Organox Ltd | 1 | $135 |
| E.r. Squibb & Sons, L.L.C. | 1 | $119 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $107 |
| Intuitive Surgical | 1 | $60 |
| AbbVie | 2 | $51 |
| Intra-sana Laboratories | 2 | $37 |
| Amgen | 1 | $32 |
| Johnson & Johnson | 1 | $24 |
| Pentax Of America, Inc. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Mirum Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GLASSIA$1,020
- LIVERguard$239
- TRINAV INFUSION SYSTEM$229
- CUVRIOR$157
- TERLIVAZ$149
- Epclusa$139
- METRA$135
- DOPTELET$135
- OPDIVO$119
- uTASWako AFP-L3$115
- REZDIFFRA$110
- IQIRVO$110
How this compares
$9,753 in reported general payments places this provider in the 70th percentile of 36 transplant hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant hepatology in New York
- Nikolaos PyrsopoulosNew York$251K
- James ParkNew York$81K
- Amon AsgharpourNew York$58K
- Giuseppe CullaroNew York$50K
- Julia WattacherilNew York$37K
- Gene ImNew York$15K
- Elizabeth VernaNew York$11K
- Rajani SharmaNew York$11K
- Annmarie LiapakisNew York$10K
- Linda LawNew York$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.